v3.25.4
Segment Reporting and Disaggregation of Relevant Expense Captions
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting and Disaggregation of Relevant Expense Captions Segment Reporting and Disaggregation of Relevant Expense Captions
Neurocrine Biosciences operates as a single global business segment dedicated to the research and development, commercialization, and sale of pharmaceuticals primarily in the U.S. for the treatment of under-addressed neurological, psychiatric, endocrine, and immunological disorders. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.
The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief operating decision maker (CODM) in assessing segment performance and deciding how to allocate resources on a consolidated basis.
The CODM assesses performance for the segment and decides how to allocate resources based on net income that also is reported on the consolidated statements of income and comprehensive income as consolidated net income. The CODM uses net income to monitor budget and forecast versus actual results in assessing segment performance and to evaluate income generated from segment assets in deciding how to allocate resources. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents information about reported segment revenues, segment profit, and significant segment expenses.
Year Ended December 31,
(in millions)202520242023
Revenues:
INGREZZA net product sales$2,513.7 $2,313.5 $1,836.0 
CRENESSITY net product sales301.2 1.7 — 
Other revenues (1)
45.640.151.1
Total revenues2,860.5 2,355.3 1,887.1 
Less:
Cost of revenues52.1 34.0 39.7 
Research and development:
External research and development 507.3 343.5 310.0 
Payroll and benefits306.4 236.7 206.7 
Milestones65.4 71.7 0.8 
Other research and development (2)
136.6 79.2 47.5 
Total research and development1,015.7 731.1 565.0 
Acquired in-process research and development17.4 12.5 143.9 
Selling, general, and administrative1,156.2 1,007.2 887.6 
Unrealized loss (gain) on equity investments4.0 37.1 (28.4)
Charges associated with convertible senior notes— 138.4 — 
Interest income and other, net(90.3)(91.0)(52.8)
Provision for income taxes226.8 144.7 82.4 
Net income
$478.6 $341.3 $249.7 
_________________________
(1) Other revenues primarily consist of net product sales of ALKINDI and EFMODY and royalties earned on AbbVie net sales of elagolix and TPC net sales of valbenazine.
(2) Other research and development consists of indirect costs incurred for the benefit of multiple research and development programs, including facility-based expenses (such as rent expense) and other overhead allocations.